By Kristy Dorsey
A freshly-minted spin-out business from the University of Glasgow has signed a licensing agreement with genomic analysis specialist Congenica to create a platform for targeting and tailoring cancer treatment.
Set up earlier this year, Gabriel Precision Oncology has developed software designed specifically to examine the genomics of cancer patients. This covers the interpretation of how all an individual’s genes interact with one another to identify their combined influence on that person’s health.
Cambridge-based Congenica already has similar technology used in the identification and treatment of rare diseases. Working with Gabriel, the company will expand its genomic interpretation platform to include somatic cancer – cancer caused by genetic mutations, which is the most common cause of the disease.
READ MORE: Funding boost for new medical technology to detect Parkinson's
Gabriel was founded by Professor Andrew Biankin, Dr Susanna Cooke and Dr Philip Beer, who between them have extensive expertise in cancer genomics and therapeutic development in both academic and commercial fields.
“At the moment, too few patients have access to advanced molecular cancer diagnostics and as a consequence miss out on potential treatments and clinical trials,” Prof Biankin said. “A distributed model where laboratories and health systems around the world can do their own tests for their own patients using a standardised and comparable analytical platform will allow more patients to access precision medicine.
“Congenica’s technology is market-leading in terms of the rapid interpretation of genomic data and working together we believe that our platform will enable many more cancer patients to access new treatments.”
READ MORE: Rare cancer treatment is within touching distance
Founded on research from the Wellcome Sanger Institute and the NHS, Congenica’s software enables rapid data analysis at scale, performing 20 times faster than industry averages and providing a 30 per cent higher analytical yield. Together, it is claimed this reduces the cost of genomic interpretation by up to 95%.
The company has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies. It is also the exclusive clinical decision support partner for the NHS Genomic Medicine Service.
“This collaboration signifies the expansion of Congenica’s product platform into somatic cancer, a disease area which we believe can significantly benefit from our platform,” vice president Freddie Sharkey said.
“Gabriel brings together extensive international genomics expertise and its platform has been developed specifically to work with tumour-derived DNA. We look forward to working with Gabriel to further incorporate clinical genomics into routine cancer care.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here